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Sangeeta R. Hingorani,1 Kristy Seidel,1 Armando Lindner,2,4 Tia Aneja,1 Gary Schoch,3
George McDonald2,3Chronic kidney disease (CKD) is common after hematopoietic cell transplantation (HCT).We prospectively
measured the urinary albumin:creatinine ratio (ACR) in 142 patients. Total (intact) monomeric albumin was
determined by liquid chromatography of untreated urine samples collected weekly to day 100 after HCT.
Albuminuria was defined as ACR (mg/g creatinine). 30; proteinuria, as ACR.300. Cox and logistic regres-
sion analyses evaluated ACR as a risk factor for clinical events. The prevalence of albuminuria was 37% at
baseline, 64% at day 100, and 50% at 1 year. Proteinuria occurred in 4% of patients at baseline, in 15% at
day 100, and in 4% at 1 year. Characteristics associated with albuminuria include age, sex, donor type, hyper-
tension, and sinusoidal obstruction syndrome (SOS). Albuminuria was associated with an increased risk of
acute graft-versus-host disease (aGVHD) and bacteremia, but not acute kidney injury (AKI). Albuminuria
at day 100 was associated with CKD at 1 year (odds ratio 5 4.0; 95% confidence interval [CI] 5 1.1 to
14.6). Nonrelapse mortality (NRM) risk was elevated (hazard ratio 5 6.8; 95% CI5 1.1 to 41.5) in patients
with overt proteinuria at day 100. Albuminuria occurs frequently after HCTand is correlated with aGVHD,
bacteremia, hypertension, and progression of renal disease. Proteinuria at day 100 is associated with an 6-fold
increased risk of NRM by 1 year after HCT.
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topoietic cell transplantAlbuminuria, defined as a urine albumin:urine cre-
atinine ratio (ACR) of 30 to 300 mg/g creatinine, is
thought to be a marker of endothelial dysfunction
and inflammation, reflecting a systemic endothelial in-
jury that affects multiple organs, including the kidney.
More recent work has postulated that albuminuria re-
sults from tubular dysfunction in the trafficking and
degradation of albumin [1,2]. In both the general pop-
ulation and in cohorts of patients with specific diseases
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6/j.bbmt.2008.09.015disease) and critical illnesses, albuminuria is a marker
for adverse events and poor outcomes. For example,
in patients with hypertension and diabetes, albumin-
uria is a risk factor for cardiovascular morbidity and
mortality [3,4]. In the general population, the presence
of albuminuria predicts the later development of car-
diovascular disease and de novo chronic kidney disease
(CKD) [5]. Albuminuria can be detected in patients
with active inflammatory bowel disease and improves
when the disease is quiescent [6]. In the intensive
care unit setting, albuminuria is associated with multi-
organ failure and increased mortality [7]. Both diabetic
and nondiabetic individuals with albuminuria are at in-
creased risk for overt proteinuria and CKD [3,8-10].
To better understand the pathophysiology of
CKD in patients who have undergone hematopoietic
cell transplantation (HCT), we prospectively mea-
sured urine ACR in patients undergoing their first
transplantation. The process of HCT and its compli-
cations frequently affect tubular and glomerular func-
tion, leading to both acute and CKD. Epidemiologic
studies have identified risk factors for kidney disease
in HCT patients; however, little is known about1365
1366 Biol Blood Marrow Transplant 14:1365-1372, 2008S. R. Hingorani et al.mechanisms of injury, early markers of renal injury, or
factors that lead to progression of CKD in patients re-
ceivingHCT. In the present study, we investigated the
prevalence of albuminuria and its clinical correlates,
including outcomes related to the development of
CKD.PATIENTS AND METHODS
Patient Selection
Patients over age 2 years undergoing their first
HCTbetween 2003 and 2006 participated in this study
if they met the following eligibility criteria: baseline
creatinine at screening within normal limits for age in
children,\ 1.3 mg/dL in women, and\ 1.5 mg/dL
in men; no current angiotensin receptor blocker or
angiotensin-converting enzyme inhibitor therapy; no
history of diabetes mellitus; and a signed consent
form approved by our Institutional Review Board.
HCT Technique
All patients undergoing HCT received a prepara-
tive regimen, followed by infusion of donor hemato-
poietic cells. By convention, the day of stem cell
infusion is termed ‘‘day 0.’’ Myeloablative regimens
typically were Cy-based (with either total body irradi-
ation [TBI] or targeted busulfan [Bu]) for allogeneic
transplants; autologous graft recipients received a com-
bination regimen of Bu or Cy with other agents. Non-
myeloablative preparative regimens consisted of
fludarabine (Flu) and low-dose TBI [11]. The kidneys
are not shieldedduringTBI. Allogeneic graft recipients
received prophylaxis against acute graft-versus-host
disease (aGVHD) with immunosuppressive drugs,
usually cyclosporine (CsA) or tacrolimus plus metho-
trexate (MTX) [12]. Prophylaxis for infections included
acyclovir for patients seropositive for herpes simplex
virus (HSV), trimethoprim/sulfamethoxazole to pre-
vent Pneumocystis jirovecii infection, oral fluconazole
or itraconazole for prophylaxis for Candida infection,
and preemptive ganciclovir for cytomegalovirus
(CMV) infection in viremic patients [13-15].
Specimen Collection and Analytical Methods
Urine samples were collected from patients at
baseline, (before any conditioning therapy), weekly
through day 100 after HCT, and monthly through
the first year after HCT. Urine was collected between
8 and 10 a.m. placed immediately on ice, separated into
2-mL aliquots, and frozen at -80C until the time of
analysis. Total (intact) monomeric albumin (immuno-
reactive plus nonimmunoreactive) was measured in al-
iquots of untreated urine samples using a high-
performance liquid chromatography (HPLC) system
(model 1100; Agilent, Santa Clara, CA) with a detec-
tion limit of\ 2 mg/dL and a coefficient of variationof 0.6% at 100 mg/dL and 0.3% at 20 mg/dL. Albu-
minuria was defined as an ACR $ 30 mg/g creatinine
in a urine sample; overt proteinuria, as an ACR $ 300
mg/g creatinine.
Definition of Clinical Variables
Patient baseline characteristics analyzed included
age, sex, diagnosis, type of transplant, conditioning
therapy, and use or nonuse of TBI. The patient’s
weight, blood pressure, medications, and tempera-
ture were recorded in the morning on the day of
sample collection. The occurrence of aGVHD grade
0-I or grade II-IV, sepsis, sinusoidal obstruction syn-
drome (SOS), acute kidney injury (AKI), or hyper-
tension in the first 100 days after HCT also were
noted. AKI was defined as a doubling of baseline se-
rum creatinine within the first 100 days after HCT
[16]. Hypertension was defined as 2 blood pressure
readings . 130/80 mmHg or the need for antihyper-
tensive medication. Bacteremia was defined as the
presence of a positive blood culture. The diagnosis
of SOS was based on previously published criteria,
as applied to data obtained during days 0 through
20 (patient weights, total serum bilirubin, imaging
studies, patient symptoms, and concomitant medical
events) [17]. One of us (G.B.M.) reviewed this mate-
rial blinded to the albuminuria results. CKD was de-
fined as a glomerular filtration rate (GFR)\ 60 mL/
min/1.73 m2 at 1 year post-HCT. Baseline clinical
and demographic data for the 142 patients included
in this analysis are presented in Table 1.
Statistical Methods
ACRs were summarized overall and then by pa-
tient demographic variables (age, sex, etc.) and clinical
characteristics (TBI, donor type, hypertension, etc.) at
baseline, on day 35 post-HCT, and on day 100 post-
HCT. Wilcoxon’s rank-sum test was used to compare
ACR values between patients with different demo-
graphic and clinical characteristics at each of those
time points. The Kruskal-Wallis test was used for
the comparisons by donor type, because there are
more than 2 donor categories. The day 35 value was
the ACR measurement obtained closest to day 35
within a window of 610 days. The day 100 value was
the ACR measurement obtained closest to day 100
within a window from day 70 to day 100.
Cox regression analysis was used to evaluate ACR
as a risk factor for later development of HCT compli-
cations, including aGVHD grade II-IV, bacteremia,
and AKI. Both baseline ACR as a fixed covariate and
ACR as a time-dependent covariate were evaluated as
risk factors. For the time-dependent model, patients
lacking pretransplantation ACR measurements were
entered into the ‘‘at risk’’ cohort at the time of their
first post-HCT ACR evaluation. A unique model was
Table 1. Patient Demographic and Transplant Characteris-
tics (n 5 142)
Patient Characteristic Frequency
Age at transplantation, years
< 20 13 (9%)
20 to 39 28 (20%)
40 to 59 78 (55%)
$ 60 23 (16%)
Median age, 47
Sex
Female 52 (37%)
Male 90 (63%)
Race
African American 6 (4%)
Caucasian 114 (80%)
Hispanic 7 (5%)
Other 13 (9%)
Not available 2 (1%)
Diagnosis
Acute myelogenous leukemia 52 (37%)
MDS 29 (20%)
Chronic myelogenous leukemia 19 (13%)
Non-Hodgkin lymphoma 13 (9%)
Acute lymphocytic leukemia 8 (6%)
Multiple myeloma 6 (4%)
Chronic lymphocytic leukemia 3 (2%)
Aplastic anemia 5 (4%)
Other 7 (5%)
Donor type
Allogeneic 59 (42%)
Autologous 17 (12%)
Unrelated donor 66 (46%)
Conditioning regimen
Reduced-intensity regimens (200 cGy) 37 (26%)
Myeloablative: Cy/TBI 12 to 13.5 Gy 25 (18%)
Myeloablative: Bu, Cy only 61 (43%)
Other myeloablative regimens 19 (13%)
Baseline serum creatinine, mg/dL, median (5th
to 95th percentile)
0.9 (0.5 to 1.3)
Cy indicates cyclophosphamide; Bu, busulfan.
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AKI, and sepsis. For aGVHD, variables adjusted for
in the multivariable model were age (\ 40 and $ 40
years), donor type (unrelated vs allogeneic; autologous
transplants excluded because they are not at risk for
aGVHD), and intensity of conditioning therapy (mye-
loablative vs reduced intensity [RIC]). For AKI, the
multivariate model was adjusted for age, aGVHD
grade II-IV, SOS, and amphotericin use. In this anal-
ysis, aGVHD and amphotericin use were modeled as
time-dependent covariates. For bacteremia, the model
included adjustments for age and intensity of the
conditioning regimen. The adjustment variables in-
cluded in each model were chosen a priori, based on
previous studies and knowledge of risk factors related
to the clinical events. Although SOS is considered
a complication of transplantation, it begins during ad-
ministration of the conditioning regimen before trans-
plantation and thus could not be analyzed using the
same Cox modeling approach. Instead, ACR summa-
ries for patients with and without SOS are provided
in Table 3.
In those subjects who survived to day 100, Kaplan-
Meier curves were used to illustrate the differences insubsequent survival through 1 year post-HCT based
on the day 100 ACR value. For nonrelapse mortality
(NRM), cumulative incidence curves stratified by day
100 ACR level were provided instead. Cumulative in-
cidence methodology was needed due to the presence
of the competing risk of relapse for this endpoint.
Cox regression analysis was used to estimate the rela-
tive risk associated with day 100 ACR category and
subsequent NRM and survival. Models were adjusted
for aGVHD grade (0/I vs grade II vs grade III/IV),
bacteremia before day 100, and chronic GVHD
(cGVHD). Logistic regression also was used to evalu-
ate the association between albuminuria at day 100 and
CKD status at 1 year post-HCT adjusted for age. 40
years, cGVHD, hypertension, and diabetes. chronic
GVHD was included in this model as an indicator of
cyclosporine use.RESULTS
Study Demographics
A total of 142 patients supplied urine samples for
ACR measurement between baseline and day 100.
The median number of samples provided per patient
was 10 (range, 1 to 15). The median age at transplan-
tation was 47 years (Table 1). Sixty-three percent of
the patients were male, and 80% were Caucasian.
The 2 most common reasons for transplantation
were acute myelogenous leukemia (AML; 37%) and
myelodysplastic syndrome (MDS 20%). Fifty-nine
(42%) patients received an allogeneic transplant from
a related donor; 66 (46%), from an HLA-matched
unrelated donor. The median serum creatinine at
baseline was 0.9 mg/dL, and 90% of baseline observa-
tions were between 0.5 and 1.3 mg/dL. After HCT, 42
patients developed AKI, 48 patients developed bacter-
emia within the first 100 days, and 20 patients devel-
oped SOS. Eighty-two patients were diagnosed with
grade II-IV aGVHD before day 100. Twenty-seven
patients developed CKD at 1 year post-HCT. Five pa-
tients died on or before day 100 and 28 died between
day 100 and 1 year post-HCT.
Prevalence of Albuminuria
The prevalence of albuminuria was 37% at base-
line and 64% by day 100 post-HCT (Table 2). Overt
proteinuria was seen in 4% of patients at baseline
and in 15% of patients by day 100 post-HCT. Of the
46 patients who were evaluated at 1 year, 50% had
albuminuria and 4% had overt proteinuria.
Clinical Associations with Albuminuria from
Day 0 to Day 100
ACR levels were generally higher in patients over
age 40 years. Men and women had similar ACR
Table 2. Descriptive Summary of ACR Values at Key Time
Points after HCT
Time
Point
Patients with
Data Available
at This Time, n
ACR, Median
(Range)
Patients with
ACR $ 30, %
Patients with
ACR $ 300, %
Pre-HCT 94 20 (1.5, 1346) 37% 4%
Day 35* 133 68 (4.7, 16948) 76% 17%
Day 100† 121 57 (1.4, 3367) 64% 15%
1 year‡ 46 31 (4.4, 494) 50% 4%
HCT indicates hematopoietic cell transplantation; ACR, urine albumin:
urine creatinine ratio.
*Observation closest to day 35 within a window of +/- 10 days.
†Observation closest to day 100 within the window d70-d100.
‡Observation closest to day 365 within a window of +/- 90 days.
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at day 100 (Table 3). With regard to donor type,
data for post-HCT time points clearly showed in-
creasing ACR levels over time, with an increasing
HLA disparity between donor and recipient. There
was no association between ACR level and TBI as
part of the conditioning regimen. Patients with
SOS exhibited dramatically higher ACR levels within
the first week post-HCT. To a lesser degree, the dif-
ference in ACR between those patients who later de-
veloped SOS and those who did not was apparent
even at baseline, before the conditioning regimen
was started and before SOS developed. Forty percent
of patients who developed SOS had undergone HCT
for MDS, compared with 17% of patients who did
not develop SOS (P 5 .02). There were no differ-
ences in terms of age, sex, or baseline hypertension
between the SOS and non-SOS groups. Post-HCT
hypertension was associated with higher ACR at
both the day 35 and day 100 time points. At 1 year
post-HCT, 57% of patients with albuminuria hadTable 3. ACRs at Selected Time Points by Clinical Characteristics
Patient/Transplant Characteristic Baseline ACR, Median (Range)
Age < 40 years 14 (2 to 424)
Age $ 40 years 24 (2 to 1346)
P 5 .05
Female 20 (2 to 1346)
Male 20 (2 to 517)
P 5 .54
No TBI 19 (2 to 517)
TBI 27 (3 to 1346)
P 5 .19
Autologous donor 32 (8 to 291)
Allogeneic (related) donor 15 (2 to 1346)
Allogeneic HLA-matched unrelated donor 23 (2 to 517)
P 5 .12
No SOS 19 (2 to 1346)
SOS 40 (8 to 319)
P 5 .02
No hypertension 20 (2 to 517)
Hypertension 22 (3 to 1346)*
P 5 .67
ACR indicates urine albumin:urine creatinine ratio; TBI, total body irradiation
*Defined as elevated blood pressure measured between study enrollment and
†Defined as elevated blood pressure on at least 2 consecutive measurementshypertension, compared with 33% of those without
albuminuria (P 5 .12).
Albuminuria as a Predictor of Clinical Events
before Day 100
The presence of albuminuria at baseline and before
the diagnosis of clinical events was used in this analysis.
Albuminuria was associated with an increased risk of
developing aGVHD and bacteremia, but not AKI (Ta-
ble 4). To further explore the potential clinical applica-
tions of this finding, the risk differential estimated
using the baseline ACR observation alone was con-
trasted with a predictive model that incorporated the
serial ACR observations as a time-dependent variable
in Cox regression. The presence of albuminuria at
baseline was associated with a 2-fold increased risk of
bacteremia during the first 100 days post-HCT. Of
the 43 patients who were diagnosed with bacteremia
before day 100 and who had sufficient ACR data for in-
clusion in the Cox regression analyses, 24 patients had
already exhibited an ACR .30 before HCT, either at
baseline or during conditioning. For the remaining pa-
tients with bacteremia without elevated ACR before
HCT, 18 patients developed ACR . 30, a median of
19 days before the diagnosis of bacteremia (interquar-
tile range [IQR], 14 to 33 days) and 1 patient did not
develop ACR . 30 before being diagnosed with
bacteremia.
Albuminuria at baseline was not significantly asso-
ciated with the development of aGVHD after adjust-
ing for other factors, but including albuminuria as
a time-varying term yielded a statistically significant
relative risk of 1.8 (95% confidence interval [CI] 5
1.0 to 3.2). Of the 78 patients who were diagnosed
with aGVHD grade II-IV before day 100 and whoDay 35 ACR, Median (Range) Day 100 ACR, Median (Range)
41 (5 to 5644) 29 (1 to 1490)
80 (10 to 16,948) 70 (9 to 3367)
P 5 .11 P 5 .04
92 (10 to 2863) 91 (7 to 3367)
59 (5 to 16,948) 45 (1 to 1490)
P 5 .32 P 5 .04
63 (7 to 16,948) 59 (3 to 3367)
98 (5 to 2863) 53 (1 to 1490)
P 5 .31 P 5 .98
41 (13 to 106) 25 (9 to 88)
59 (5 to 5644) 45 (1 to 3367)
96 (8 to 16,948) 90 (3 to 1490)
P 5 .04 P 5 .006
60 (5 to 16,948) 45 (1 to 3367)
231 (23 to 5644) 129 (21 to 822)
P 5 .0006 P 5 .01
52 (5 to 5644) 30 (1 to 3367)
121 (8 to 16,948)† 100 (3 to 1490)
P 5 .0001 P 5 .0005
; SOS, sinusoidal obstruction syndrome.
the start of the conditioning regimen (day -7).
taken between HCTand the time point specified.
Table 4. Cox Regression Analysis of Albuminuria as a Pre-
dictor of Clinical Events in the First 100 Days Post-HCT
Outcome
Event
Albuminuria Term
Incorporated as
Relative Risk
(95% CI)
Adjusted Relative
Risk (95% CI)
aGVHD
grade II-IV
Time-varying 1.9 (1.1 to 3.3) 1.8 (1.0 to 3.2)
Baseline only 1.7 (1.0 to 3.0) 1.6 (0.9 to 2.8)
AKI (2  baseline
creatinine)
Time-varying 1.0 (0.5 to 1.9) 0.7 (0.3 to 1.8)
Baseline only 1.4 (0.6 to 3.3) 1.1 (0.4 to 3.2)
Bacteremia Time-varying 9.3 (2.2 to 38.5) 10.0 (2.4 to 42.0)
Baseline only 2.4 (1.1 to 5.2) 2.3 (1.0 to 5.1)
aGVHD indicates acute graft-versus-host disease; AKI, acute kidney in-
jury; HCT, hematopoietic cell transplantation.
Table 5. Cox Regression Analysis of Nonrelapse Mortality
from Day 100 through 1 Year Post-HCT
Day 100 ACR
Category
Hazard Ratio
(95% CI), Unadjusted
Hazard Ratio
(95% CI), Adjusted*
Day 100 ACR < 30 Not applicable
(baseline category)
Day 100 ACR 30 to 300 1.7 (0.3 to 9.3) 1.4 (0.2 to 7.9)
Day 100 ACR > 300 12.8 (2.7 to 60.6) 6.8 (1.1 to 41.5)
HCT indicates hematopoietic cell transplantation; ACR, urine albumin:
urine creatinine ratio; aGVHD, acute graft-versus-host disease; cGVHD,
chronic graft-versus-host disease.
*Adjusted for aGVHD grade II, grade III/IV, bacteremia and cGVHD.
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gression analyses, 35 had already exhibited an ACR
.30 before HCT, either at baseline or during condi-
tioning. Of the remaining patients with aGVHDwith-
out elevated ACR before HCT, 34 patients had an
ACR . 30 a median of 18 days before their aGVHD
grade II-IV diagnosis (IQR, 10 to 33 days), and 9 pa-
tients did not. Albuminuria was not associated with
AKI, regardless of whether it was modeled as a fixed
baseline term or as a time-varying term.
Albuminuria and 1-Year Outcomes
We evaluated how ACR information from the
acute phase of transplantation care is related to the
risk for adverse clinical outcomes from the time of dis-
charge from our transplantation center to 1 year post-
HCT. In univariate analysis, overt proteinuria at day
100 was strongly associated with increased risk of non-
relapse mortality (hazard rate [HR]5 12.8; 95% CI5
2.7 to 60.6) and overall mortality (HR5 7.7; 95%CI5
2.4 to 24.7) (Table 5). In multivariable analyses,
patients with overt proteinuria at day 100 had an almost
7-fold increased risk ofNRM(HR5 6.8; 95%CI5 1.1
to 41.5) through 1 year post-HCT after adjustment for
aGVHD grade, bacteremia before day 100, and
cGVHD. The elevation in overall mortality risk with
overt proteinuria at day 100 was less pronounced
(HR 5 2.4; 95% CI 5 0.6 to 0.7) after adjustment for
the same set of factors. Patients with a day 100 ACR
of 30 to 300 did not exhibit increased risk for nonre-
lapse or overall mortality (Figures 1 and 2). Among sur-
viving patients, 17% (5/29) of those with day 100 ACR
\30hadCKDat 1 year, comparedwith 48% (21/44) of
those with an ACR$ 30 who had CKD at 1 year post-
HCT (P\.01). AnACR$ 30 at day 100was associated
with a 4-fold increased risk of CKD (odds ratio 5 4.0;
95%CI5 1.1 to 14.6) at 1 year post-HCT after adjust-
ing for cGVHD, hypertension, diabetes, and age.DISCUSSION
This is the first study to describe the relationship of
albuminuria to clinical outcomes in the HCT popula-tion. We found that albuminuria was common after
HCT, with 94% of patients developing it at some
point within the first 100 days post-HCT. Although
albuminuria resolved in some patients, it persisted in
most, being found in 64% at day 100 post-HCT and
50% at 1 year post-HCT. Among those patients who
were alive at 1 year post-HCT, 4% had overt protein-
uria. Post-HCT ACR elevations were more pro-
nounced in patients undergoing allogeneic HCT
(especially those with an unrelated donor) compared
with those undergoing autologous HCT. Post-HCT
complications associated with higher ACR included
elevated blood pressure, liver disease with portal hy-
pertension, and bacteremia. TBI, as part of the condi-
tioning therapy, was not associated with ACR.
Compared with other populations, in which albu-
minuria can take years to develop, albuminuria occurs
rapidly after HCT, appearing before day 100 in most
patients. A study of pediatric patients found that 15%
of children developed albuminuria after conditioning
therapy and before cell infusion [18]. A follow-up study
of these patients 1 to 2 years later found that their albu-
minuria had normalized [19]. The presence of albumin-
uria in the diabetic population is suggestive of
glomerular pathology and is associatedwith progressive
loss of kidney function over time. Recent research has
focused on the direct role of albuminuria and protein-
uria in the progression of CKD [20]. Albuminuria is
thought to trigger the local release of proinflammatory
cytokines and chemokines, which recruit macrophages
andother inflammatory cells into the interstitium, caus-
ing fibrosis and progression of CKD. Similar findings
are present in the HCT population; patients with albu-
minuria at day 100 post-HCT are more likely to prog-
ress to CKD stage 3 by 1 year post-HCT.
The association between albuminuria and clinical
events post-HCT and the presence of albuminuria be-
fore the development of aGVHD and bacteremia sug-
gests that albuminuria is a marker of systemic as well as
local (within the kidney) inflammation and vascular in-
jury. Our finding of higher ACR in allogeneic trans-
plant recipients (who are more likely to develop
GVHD) compared with autologous transplant recipi-
ents further supports the association of albuminuria
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Figure 1. Cumulative incidence curves of nonrelapse mortality from
day 100 to 1 year post-HCT, displayed by degree of albuminuria (n 5
43 for ACR\ 30; n 5 54 for ACR 30 to 300; n 5 17 for ACR $ 300).
1370 Biol Blood Marrow Transplant 14:1365-1372, 2008S. R. Hingorani et al.and GVHD. GVHD can cause direct endothelial in-
jury through cytotoxic T lymphocytes, in addition to
a proinflammatory cytokine profile [21] Tissue de-
struction by aGVHD does not require alloantigen ex-
pression on target epithelium for cellular cytotoxicity;
injury also can be mediated by inflammatory cytokines
[22]. Both minimal-change nephrotic syndrome and
membranous nephropathy post-HCT are thought to
be manifestations of GVHD in the kidney [23,24]. In
minimal-change nephrotic syndrome following
HCT, increased production of tumor necrosis fac-
tor-a and interferon-g by donor T cells has been asso-
ciated with the development of nephrotic syndrome;
the lack of cellular infiltrates on biopsy suggests that
the glomerular injury occurs secondary to cytokine
production stimulated by alloantigens at extrarenal
sites [25]. In membranous nephropathy, subepithelial
immune complex deposition is present along the
glomerular basement membrane. There also is some
evidence suggesting that albuminuria is caused by0.00
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Figure 2. Kaplan-Meier curves of overall survival from day 100 to 1
year post-HCT, by degree of albuminuria (n 5 44 for ACR\ 30; n 5
58 for ACR 30 to 300; n 5 18 for ACR $ 300).defective tubular trafficking and degradation of albu-
min [1,2]. It may be that in HCT patients, inflamma-
tory damage to the tubules from GVHD leads to
albuminuria, which is a manifestation of renal
GVHD. These findings support the hypothesis that
albuminuria is a subclinical marker of GVHD that
can be detected before the disease clinically manifests
in the gut, skin, and liver. These data also suggest
that the renal vasculature, glomerulus, and perhaps
the proximal tubular cells are affected by the GVHD
process, making the kidney another target organ in
aGVHD.
Among persons with diabetes or hypertension, as
well as in the general population, the presence of
albuminuria is associated with an increased risk of car-
diovascular morbidity and mortality even after adjust-
ment for other known risk factors [3,4,26,27]. We
found an increased risk of NRM and decreased overall
survival (OS) in patients with proteinuria at day 100
post-HCT independent of aGVHD grade, cGVHD,
and bacteremia. Although the cause of death in the
HCT population often is multifactorial (with many
patients dying from infections, complications of
GVHD, and/or relapse of their primary disease), our
data do not address the mechanisms by which the pres-
ence of proteinuria confers an additional risk in this pa-
tient population.
Our findings have some clinical implications. First,
the incidence of renal injury as detected by the pres-
ence of albuminuria is higher than has been found in
previous studies using serum creatinine level and esti-
mated GFR. The presence of albuminuria may be
a marker of both systemic and renal inflammation
and vascular injury perpetuated by bacteremia and/or
aGVHD. These data suggest that both inflammation
and vascular injury may play a role in the development
of renal disease in this patient population. Second,
albuminuria may serve as a useful clinical marker of
patients at increased risk for late complications post-
HCT, specifically the development of CKD at 1 year
post-HCT. We recommend that all patients undergo
routine urinalysis at baseline and at day 100 post-
HCT, to identify those at high risk for these adverse
long-term outcomes. Although we found an increased
risk for CKD in patients with albuminuria at day 100
post-HCT and an increased risk of NRM in patients
with overt proteinuria, whether intervention to reduce
the albuminuria or proteinuria will prove beneficial in
this patient population remains unknown. Some evi-
dence indicates that in patients with diabetes and albu-
minuria, treatment with an angiotensin-converting
enzyme inhibitor (ACEI) or an angiotensin receptor
blocker (ARB) can slow the progression of CKD
[28,29]. Extrapolating from the studies in the diabetic
population, we speculate that ACEI or ARB therapy
may be useful in patients with albuminuria post-
HCT; however, clinical trials using an ACEI or ARB
Biol Blood Marrow Transplant 14:1365-1372, 2008 1371Albuminuria in HCT Patientsto treat HCT patients with albuminuria at day 100
post-HCT are needed to correlate albuminuria with
progression to end-stage renal disease and to deter-
mine whether or not interventions to reduce albumin-
uria and proteinuria can affect outcomes in the HCT
population. A recent study using captopril after en-
graftment in 55 patients who underwentHCT demon-
strated a trend toward improvement in 1-year GFR
and serum creatinine level compared with untreated
patients [30].
In summary, albuminuria occurs frequently in the
HCT population and is associated with subsequent
aGVHD, bacteremia, and progressive renal disease.
Overt proteinuria at day 100 post-HCT is associated
with a 6-fold increased risk of NRM and a decrease in
OS in patients at 1 year post-HCT. In the HCT popu-
lation, renal injuryoccurs early afterHCT, is not always
reflected by changes in serum creatinine level, and af-
fects long-term outcomes.ACKNOWLEDGMENTS
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